

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Spesolimab for treating acute generalised pustular psoriasis ID3963

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Boehringer Ingelheim Ltd (spesolimab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> Changing Faces Genetic Alliance UK Gene People Psoriasis and Psoriatic Arthritis Alliance Psoriasis Association Psoriasis Help Organisation South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses & Counsellors British Association of Dermatologists British Dermatological Nursing Group British Geriatrics Society British Society for Cutaneous Allergy British Society for Genetic Medicine Primary Care Dermatology Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine St John's Institute of Dermatology UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health and Social Care NHS England 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> AbbVie (adalimumab, risankizumab) Accord Healthcare (methotrexate) Advanz Pharma (methotrexate) Almirall (dimethyl fumarate, tildrakizumab) Amgen (adalimumab, apremilast) Biogen Idec (adalimumab, dimethyl fumarate, etanercept, infliximab) Celltrion Healthcare UK (adalimumab, infliximab) Colorama / B&S group (ciclosporin) Dexcel-Pharma (ciclosporin) Eli Lilly and Company (ixekizumab)

Provisional stakeholder list for the evaluation of spesolimab for treating acute generalised pustular psoriasis ID3963

Issue date: September 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • Fresenius Kabi (adalimumab) • Genus Pharmaceuticals (acitretin) • Hospira UK (methotrexate) • Janssen-Cilag (guselkumab, ustekinumab) • Leo Pharma (brodalumab) • Medac GmbH (methotrexate) • Morningside Healthcare (acitretin, ciclosporin, methotrexate) • MSD (infliximab) • Mylan (ciclosporin) • Nordic Pharma (methotrexate) • Novartis Pharmaceuticals UK (ciclosporin, secukinumab) • Orion Pharma (UK) (methotrexate) • Pfizer (etanercept, infliximab, methotrexate) • Rosemont Pharmaceuticals (methotrexate) • Sandoz (adalimumab, etanercept, infliximab, methotrexate) • Santen UK (ciclosporin) • Teva UK (acitretin, ciclosporin, methotrexate) • Therakind Limited (methotrexate) • UCB Pharma (bimekizumab, certolizumab pegol) • Viartis (ciclosporin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Skin Foundation • Centre of Evidence-based Dermatology, University of Nottingham • Cochrane Cystic Fibrosis & Genetic Disorders Group • Cochrane Skin Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

Provisional stakeholder list for the evaluation of spesolimab for treating acute generalised pustular psoriasis ID3963

Issue date: September 2022

© National Institute for Health and Care Excellence 2022. All rights reserved.

Page 2 of 3

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.